Vernalis plc

Vernalis plc was a UK-based pharmaceuticals business headquartered in Winnersh, with research in Cambridge, and with a Berwyn, PA, US-based commercial operation, Vernalis Therapeutics Inc., focusing on the sales and marketing of slow-release formulations of prescription cough and cold medicines. Tuzistra XR (codeine polistirex/ chlorpheniramine polistirex) was the first launched product which arose from this strategy,[1] however sales did not reach expectations.[2] As a result, the strategy was abandoned and the company was put up for sale.[3] Vernalis plc was listed on AIM until its acquisition by Ligand Holdings (UK) Ltd, a subsidiary of Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) on 10 October 2018.[4]

Vernalis plc

Former type	Public
Industry	Pharmaceuticals
Fate	Acquired
Predecessor	British Biotech, Vernalis Group
Successor	Vernalis Research, a Ligand Company
Founded	2003
Defunct	2018
Headquarters	Winnersh, UK
Key people	Chairman: Peter Fellner (2003-2018), CEO Simon J. Sturge (2003-2008), Ian R. Garland (2008-2018)

Vernalis plc (formerly known as British Biotech plc prior to 1 October 2003), arose from two company mergers.[5] The first merger, with the privately held Cambridge-based RiboTargets Holdings plc, was completed in April 2003, and brought a structure-based drug discovery capability focused on novel cancer targets.[6] The second merger, with Vernalis Group, was completed in September 2003 and brought a marketed product, frovatriptan, a clinical portfolio and drug discovery programmes focused on CNS disorders.[7]

Its successful Cambridge, UK-based research facility, with expertise in fragment and structure-based drug discovery, continues as Vernalis Research, a Ligand Company. The company is engaged in research collaborations with pharmaceuticals industry partners, and maintains a pipeline of commercially partnered and non-partnered drug candidates in pre-clinical and clinical development.